Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$238.75 USD

238.75
1,334,422

-5.37 (-2.20%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Down

ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.

ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

ResMed (RMD) Beats Q1 Earnings and Revenue Estimates

ResMed (RMD) delivered earnings and revenue surprises of 0.61% and 0.51%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ResMed (RMD) Gains From Strong Device Sales Amid Macro Woes

ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business.

ResMed (RMD) Stock Jumps 3.8%: Will It Continue to Soar?

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ResMed (RMD) Gains From Mask Sales Amid Macro Headwinds

ResMed's (RMD) respiratory care business continues to drive growth, courtesy of the adoption of bilevel and other non-invasive ventilator solutions worldwide.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD), backed by the continued demand for digital health solutions.

ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates

ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.

Compared to Estimates, ResMed (RMD) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ResMed (RMD) Misses Q4 Earnings Estimates

ResMed (RMD) delivered earnings and revenue surprises of -4.19% and 0.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for ResMed (RMD)

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout

ResMed (RMD) announces the acquisition of the Somnoware diagnostic management platform.

ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs

ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.

ZBH vs. RMD: Which Stock Should Value Investors Buy Now?

ZBH vs. RMD: Which Stock Is the Better Value Option?

ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates

ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.

ResMed (RMD) Q3 Earnings and Revenues Beat Estimates

ResMed (RMD) delivered earnings and revenue surprises of 7.01% and 7.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.

EYE vs. RMD: Which Stock Should Value Investors Buy Now?

EYE vs. RMD: Which Stock Is the Better Value Option?

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.

Sheraz Mian headshot

Top Research Reports for Chevron, Novo Nordisk & Amgen

Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Novo Nordisk A/S (NVO) and Amgen Inc. (AMGN).